Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease

Ashwini Arvind, Jacqueline B. Henson, Stephanie A. Osganian, Cheryl Nath, Lara M. Steinhagen, Zoe N. Memel, Arley Donovan, Oluwafemi Balogun, Raymond T. Chung, Tracey G. Simon, Kathleen E. Corey – 1 September 2021 – Nonalcoholic fatty liver disease (NAFLD) is independently associated with obesity and cardiovascular disease (CVD). CVD is the primary cause of mortality in the predominantly obese population of adults with NAFLD.

Predictors of Jaundice Resolution and Survival After Endoscopic Treatment of Primary Sclerosing Cholangitis

John E. Eaton, Abdul Haseeb, Christian Rupp, Leonardo H. Eusebi, Kim Munster, Robert Voitl, Douglas Thorburn, Cyriel Y. Ponsioen, Felicity T. Enders, Bret T. Petersen, Barham K. Abu Dayyeh, Todd H. Baron, Vinay Chandrasekhara, Christopher J. Gostout, Michael J. Levy, John Martin, Andrew C. Storm, Ross Dierkhising, Patrick S. Kamath, Gregory J. Gores, Mark Topazian – 31 August 2021 – The benefit of endoscopic retrograde cholangiopancreatography (ERCP) for the treatment of primary sclerosing cholangitis (PSC) remains controversial.

Correlation Between Clinical and Pathological Findings of Liver Injury in 27 Patients With Lethal COVID‐19 Infections in Brazil

Monique Freire Santana, Mateus T. Guerra, Melanie A. Hundt, Maria M. Ciarleglio, Rebecca Augusta de Araújo Pinto, Bruna Guimarães Dutra, Mariana Simão Xavier, Marcus Vinicius Guimarães Lacerda, Anderson Jose Ferreira, David Campos Wanderley, Israel Júnior Borges do Nascimento, Roberto Ferreira de Almeida Araújo, Sérgio Veloso Brant Pinheiro, Stanley de Almeida Araújo, M. Fatima Leite, Luiz Carlos de Lima Ferreira, Michael H.

Breakthrough Hepatitis B Virus Infection in a Liver Transplant Recipient on Lamivudine Prophylaxis for Donor Hepatitis B Core Antibody Seropositivity: A Review of Practices to Prevent De Novo Hepatitis B Virus Infection After Transplant

Subscribe to